Skip to content

Study · Randomized controlled trial · n = 61 · 2025

1 result

Arginine-Vasopressin Dynamics in Relation to Food Intake and 8-Week Intranasal Oxytocin Treatment in Adults With Obesity.

Aulinas A, Galbiati F, Wronski ML, Carter CS, Nazarloo S, Holman K, Golden ER, Muhammed M, Hadaway N, Asanza E, Smith SE, Plessow F, Lawson EA

The Journal of clinical endocrinology and metabolism1 Nov 2025Cited by 2 (Europe PMC)

PMID40314146 (opens in a new tab)PMCIDPMC12623050 (opens in a new tab)DOI10.1210/clinem/dgaf237 (opens in a new tab)PepBankPUB-40314146
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialMechanism

    In adults with obesity, 8 weeks of intranasal oxytocin did not significantly change arginine-vasopressin levels compared with placebo.

    In plain wordsIn adults with obesity, 8 weeks of nasal oxytocin did not change vasopressin levels compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeArginine-vasopressin levels over 8 weeks of intranasal oxytocin
    Study

    n = 61

    Comparator
    Placebo
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    24 IU four times daily · intranasal · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    AVP levels did not significantly change over the course of 8-W IN OXT treatment vs placebo (P ≥ .544).
    1 context sentence
    Summary · context
    Participants included 63 adults with obesity (56% women, age 33.7 ± 6.3 years) of whom 61 were randomly assigned 1:1 to 8-W IN OXT (24 IU) 4 times daily or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.